Inrebic

Fedratinib, the active ingredient in Inrebic, is a JAK2 inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of myelofibrosis in adult patients.

GNH USA supplies Inrebic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Inrebic targets the JAK‑STAT signaling pathway that drives myeloproliferative neoplasms. It is approved for the following conditions: - Primary myelofibrosis: reduces spleen size and alleviates disease‑related symptoms. - Post‑polycythemia vera myelofibrosis: improves hematologic parameters and quality of life. - Post‑essential thrombocythemia myelofibrosis: decreases splenomegaly and symptom burden.

Adverse reactions to Inrebic may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often self‑limiting. - Fatigue: persistent tiredness affecting daily activities. - Anemia: reduced red blood cell count. - Thrombocytopenia: lowered platelet levels. - Vomiting: occasional episodes after dosing.

Serious or Rare Side Effects: - Wernicke encephalopathy: neurological syndrome requiring immediate attention. - Severe infections: heightened risk due to immunosuppression. - Hepatic toxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced cardiac function. - Tumor lysis syndrome: metabolic disturbances in high‑risk patients. - Severe neutropenia: markedly low neutrophil count increasing infection risk.

Before initiating Inrebic, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect anemia, thrombocytopenia, or neutropenia. - Assess liver function: periodic LFTs are recommended. - Evaluate neurological status: watch for early signs of Wernicke encephalopathy. - Avoid in patients with known hypersensitivity to fedratinib or its excipients. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Fedratinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase fedratinib exposure. - Concomitant use with other JAK inhibitors: may cause additive myelosuppression. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fedratinib plasma levels. - Anticoagulants (e.g., warfarin): monitor for altered bleeding risk. - Antifungal azoles (e.g., fluconazole): may modestly raise fedratinib concentrations.